Eftilagimod alfa

Immutep Limited has initiated a multinational Phase III trial for its cancer drug eftilagimod alfa, focusing on non-small cell lung cancer. The trial will be conducted at 150 sites across 25 countries, with the first patient expected to be enrolled in Q1 2025. The drug will be tested in combination with Keytruda and chemotherapy. Immutep also presented positive trial data on eftilagimod alfa for head and neck cancers at the European Society for Medical Oncology’s Immuno-Oncology Congress 2024.

Immutep initiates TACTI-004 Phase III trial for 1L metastatic NSCLC, evaluating eftilagimod alfa with KEYTRUDA and chemotherapy. First regulatory approval in Australia, with global trial in over 25 countries expected to enroll first patient in Q1 2025.

Immutep (ASX:IMM) initiates TACTI-004 Phase III trial to evaluate eftilagimod alfa (efti) for first-line metastatic NSCLC, in combination with Keytruda and chemotherapy vs. standard treatment. The double-blind study will enroll ~750 patients across 150+ sites in 25+ countries, measuring progression-free and overall survival. CEO Marc Voigt highlights potential for new standard of care, with first patient enrollment expected Q1 2025.

Immutep announced the initiation of its TACTI-004 Phase III trial for eftilagimod alfa in combination with KEYTRUDA and chemotherapy for first-line metastatic NSCLC. The trial aims to establish eftilagimod alfa as a new standard of care, with enrollment expected in Q1 2025. Over 25 countries will participate, and Immutep has regulatory filings in most regions. The company had A$172.3 million in cash and equivalents as of Sep. 30, 2024.

Immutep Limited announces the initiation of the TACTI-004 Phase III trial for first-line metastatic non-small cell lung cancer, marking its transformation into a Phase III company. The trial will evaluate eftilagimod alfa in combination with KEYTRUDA and chemotherapy, aiming to establish a new standard of care. Enrollment is expected in Q1 2025.

Immutep Limited launched TACTI-004 Phase III trial for metastatic non-small cell lung cancer, assessing LAG-3 immunotherapy eftilagimod alfa with KEYTRUDA and chemotherapy. First patient enrollment expected early 2025.